Human Stem Cells Institute to develop ischemia drug in U.S. and Canada
Thursday, October 13, 2016
Human Stem Cells Institute Says it has licensed the exclusive U.S. and Canadian rights for Neovasculgen to ArtGen, Inc., a privately held biotechnology company located in Rockville, MD.
Neovasculgen is a first-in-class gene therapy drug that was approved in 2011 for human use in Russia for treatment of atherosclerotic Peripheral Arterial Disease, including Critical Limb Ischemia.
Says it will receive milestone payments, royalties and future equity participation rights in ArtGen.
Source : reuters.com
